MK-3207 represents the third CGRP receptor antagonist to display clinical efficacy in migraine trials. It is a potent CGRP receptor antagonist with IC50 and Ki of 0.12 nM and 0.022 nM, highly selective versus human AM1, AM2, CTR, and AMY3. MK-3207 had been in phase II clinical trials by Merck Sharp & Dohme for the treatment of migraine. But the company had discontinued the research due to asymptomatic liver test abnormalities in 2010.

LAUROLINIUM, a quaternary ammonium compound, is a cationic antimicrobial agent. It has a broad spectrum of activity against Gram‐positive and Gram‐negative bacteria, fungi, and protozoan Trichomonas vaginalis. It is suitable for use in the treatment of local infections, for the sterilization of skin areas and for general antiseptic purposes.

Ampyzine is a pyrazine derivative patented by Warner-Lambert Pharmaceutical Co. as a central nervous system stimulant.

Anatibant was a selective small-molecule antagonist of the bradykinin B2 receptor that was undergoing clinical development with Xytis and Fournier for the treatment of brain injuries. Anatibant reduces brain oedema in animal TBI models. Noserious toxicity was found in Phase 1 clinical trials. Following subcutaneous administration of clinically relevant doses, there were no systemic effects but there was pain, inflammation and nodule formation at the injection site. Anatibant inhibits the binding of BK to the B2 receptor. After subcutaneous injection Anatibant is bio-available and crosses the BBB.

Atigliflozin (also known as AVE2268), a substituted glycopyranoside, is a selective inhibitor of sodium-dependent glucose transporter 2. This drug reached phase II clinical trials as a new antidiabetic drug for the treatment of type 2 diabetes but further development was discontinued.

Tibeglisene (also known as BM 13907) is a pentynoic acid derivative patented by Boehringer Mannheim G.m.b.H. as insulin sensitizer with hypoglycemic activity. Tibeglisene is also able to reduce serum triglyceride and cholesterol concentrations. Tibeglisene exerts favor influences on glucose-transport activity.

Fonturacetam, also known as Phenylpiracetam, is marketed in Russia as Carphedon and Phenotropil. It is one of the first ever nootropic drugs and originally discovered in Russia. Fonturacetam acts on most neurotransmitter systems and has been used for its cognitive and physical enhancing properties, and also as an antidepressant.

Veliparib (ABT-888) is a potent inhibitor of PARP, has good oral bioavailability, can cross the blood-brain barrier, and potentiates temozolomide, platinums, cyclophosphamide, and radiation in syngeneic and xenograft tumor models. AbbVie is developing veliparib for the treatment of cancers. Clinical trials are underway worldwide, investigating veliparib primarily as part of a combination therapy in oncology indications such as brain, colorectal, melanoma, ovarian, prostate and pancreatic cancers.

Propazolamide is a sulfonamide derivative patented by American Cyanamid Co. useful in the treatment of glaucoma and epilepsy and as oral diuretics. Propazolamide acts as a carbonic anhydrase inhibitor.